Skip to main content
α
中文

AI-generated · Based on company filings and platform data · Not investment advice

Earnings Brief AMGN

Amgen (AMGN) Q3 2026 Earnings Brief: Revenue $10.37B, +8.5% YoY

Released Nov 3, 2026 (ET)

Quarter: Q3 2026, period ended 2026-09-30; released 2026-11-03 (ET).

In one line: Amgen's revenue in the third quarter of 2026 was US$10.37 billion, with adjusted earnings per share of US$6.45, exceeding analysts' consensus expectations by 11.6%.

Key numbers

MetricThis quarterNote
Revenue$10.37BYoY +8.5%
Adj. EPS vs consensus$6.45 vs $5.78Beat (+11.6%)
GAAP diluted EPS$7.08Different basis from consensus
Net margin37.3%Net income $3.86B
Next-quarter EPS consensus$5.6327 analysts; revenue consensus $10.47B

Three things to know

1. Revenue increased by 8.5% year-on-year

Revenue for the quarter was US$10.37 billion, an increase of 8.5% from US$9.56 billion in the same period last year, reflecting the continued expansion of the core product line.

2. Net profit margin reached 37.3%

The net profit margin for the quarter was 37.3%, corresponding to net income of US$3.86 billion, indicating that the company's profitability remains stable.

3. Adjusted EPS beat expectations

Adjusted earnings per share were $6.45, which was 11.6% higher than analysts’ consensus estimate of $5.78.

Market reaction

Results were released on 2026-11-03 (ET). From the last pre-report close (2026-11-02, $465.45) to the close of the first session after the report (2026-11-04, $478.48), the stock moved +2.80%. The report-day close was $461.26; the next session closed +3.73% from it (for after-hours releases, this leg better reflects the reaction to the report).

What to watch next

  • Pay attention to the fourth quarter financial report date of 2026 (February 2, 2027) and the consensus EPS average of $5.63 for the next quarter.
  • Pay attention to management’s explanation of clinical trial progress and regulatory developments in subsequent communications.
  • Observe whether capital expenditure and R&D investment in the first nine months are in line with the established plan.
  • Next report date (platform calendar): 2027-02-02

Sources

  • Financials: fundamentals-svc (EDGAR filings, analyst consensus)
  • Prices: fundamentals-svc /v1/candles-ondemand
  • MD&A source: 10-Q (filed 2026-11-04)
  • Company press release (8-K): SEC EDGAR

Read the Amgen (AMGN) stock report →

← All earnings briefs